Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00042900 | Pyroxamide in Treating Patients With Advanced Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
| completed |
| Phase 1 |
| 24 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jun 5, 2013 |
| clinicaltrials |
| NCT00017472 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00062244 | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00109824 | Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00058396 | Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00059995 | MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00061880 | BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | — | BioCryst PharmaceuticalsINDUSTRY | 1 | May 30, 2013 | clinicaltrials |
| NCT00659568 | Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma | completed | Phase 1 | 28 | London Health Sciences CentreOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00006009 | Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma | completed | Phase 1 | — | Stanford UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00070421 | Study of @neWorld: A Virtual Community for Children With Cancer | completed | Phase 1 / Phase 2 | — | Leap of Faith TechnologiesINDUSTRY | 1 | May 15, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00006368 | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00003425 | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | completed | Phase 1 / Phase 2 | 25 | University of KentuckyOTHER | 1 | Apr 26, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT00698243 | Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 128 | Astellas Pharma IncINDUSTRY | 3 | Apr 15, 2013 | clinicaltrials |
| NCT00004162 | Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma | completed | Phase 1 | 48 | University of Alabama at BirminghamOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00003956 | Combination Chemotherapy in Treating Patients With Advanced Cancer | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00003406 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer | completed | Phase 1 / Phase 2 | 30 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00003368 | Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00379574 | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | completed | Phase 1 / Phase 2 | 49 | Asan Medical CenterOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00215605 | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | completed | Phase 1 | 85 | ExelixisINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00002750 | Melphalan in Patients With Neoplastic Meningitis | completed | Phase 1 | 6 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00823524 | Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00002980 | Decitabine in Treating Patients With Melanoma or Other Advanced Cancer | completed | Phase 1 | — | California Cancer ConsortiumNETWORK | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00544284 | Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00962507 | Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | completed | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT01074060 | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00428545 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | completed | Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00002625 | Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00002862 | Perillyl Alcohol in Treating Patients With Refractory Cancer | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00002946 | Penclomedine in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00004101 | Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00004189 | Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00005967 | Tipifarnib in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00006221 | BMS-247550 in Treating Patients With Advanced Cancers | completed | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2013source: clinicaltrials